Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine. The Cambridge, Massachusetts-based biotech is also laying off staffers and CEO Keith ...

-- Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT; initiated IND-enabling activities for Wilson’s Disease program in 4Q 2024 and remains on track ...

Prime Medicine Inc. (NASDAQ:PRME) is one of the best hot stocks to buy according to Wall Street analysts. In May, Prime Medicine announced a strategic restructuring, which included a reprioritization ...

CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...

Prime Medicine, Inc. (PRME – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading maintained a Buy rating on the stock ...

-- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- ...

We recently compiled a list of the 10 Most Shorted Stocks That Are Loved by Analysts. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other ...

Prime Medicine announces positive Phase 1/2 data for PM359, leadership changes, and strategic pipeline prioritization, focusing on liver diseases. Prime Medicine, Inc. announced initial positive data ...

Good day, and thank you for standing by. Welcome to the Prime Medicine Wilson Disease KOL Event Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I ...

Prime Medicine shares were 9.2% lower, at $3.90, after the company said the Cystic Fibrosis Foundation has agreed to provide it with up to $24 million in additional funding--including a $6 million ...